These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29709465)

  • 1. Huntington's disease pattern of transcriptional dysregulation in the absence of mutant huntingtin is produced by knockout of neuronal GLT-1.
    Laprairie RB; Petr GT; Sun Y; Fischer KD; Denovan-Wright EM; Rosenberg PA
    Neurochem Int; 2019 Feb; 123():85-94. PubMed ID: 29709465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of Neuronal GLT-1 in Mice Reveals Its Role in Synaptic Glutamate Homeostasis and Mitochondrial Function.
    McNair LF; Andersen JV; Aldana BI; Hohnholt MC; Nissen JD; Sun Y; Fischer KD; Sonnewald U; Nyberg N; Webster SC; Kapur K; Rimmele TS; Barone I; Hawks-Mayer H; Lipton JO; Hodgson NW; Hensch TK; Aoki CJ; Rosenberg PA; Waagepetersen HS
    J Neurosci; 2019 Jun; 39(25):4847-4863. PubMed ID: 30926746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional Knockout of GLT-1 in Neurons Leads to Alterations in Aspartate Homeostasis and Synaptic Mitochondrial Metabolism in Striatum and Hippocampus.
    McNair LF; Andersen JV; Nissen JD; Sun Y; Fischer KD; Hodgson NW; Du M; Aoki CJ; Waagepetersen HS; Rosenberg PA; Aldana BI
    Neurochem Res; 2020 Jun; 45(6):1420-1437. PubMed ID: 32144526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.
    Petr GT; Schultheis LA; Hussey KC; Sun Y; Dubinsky JM; Aoki C; Rosenberg PA
    Eur J Neurosci; 2013 Aug; 38(3):2477-90. PubMed ID: 23586612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axon-terminals expressing EAAT2 (GLT-1; Slc1a2) are common in the forebrain and not limited to the hippocampus.
    Zhou Y; Hassel B; Eid T; Danbolt NC
    Neurochem Int; 2019 Feb; 123():101-113. PubMed ID: 29530756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice.
    Denovan-Wright EM; Robertson HA
    Neuroscience; 2000; 98(4):705-13. PubMed ID: 10891614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral phenotyping and dopamine dynamics in mice with conditional deletion of the glutamate transporter GLT-1 in neurons: resistance to the acute locomotor effects of amphetamine.
    Fischer KD; Houston ACW; Desai RI; Doyle MR; Bergman J; Mian M; Mannix R; Sulzer DL; Choi SJ; Mosharov EV; Hodgson NW; Bechtholt A; Miczek KA; Rosenberg PA
    Psychopharmacology (Berl); 2018 May; 235(5):1371-1387. PubMed ID: 29468294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice.
    Liévens JC; Woodman B; Mahal A; Spasic-Boscovic O; Samuel D; Kerkerian-Le Goff L; Bates GP
    Neurobiol Dis; 2001 Oct; 8(5):807-21. PubMed ID: 11592850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation.
    Behrens PF; Franz P; Woodman B; Lindenberg KS; Landwehrmeyer GB
    Brain; 2002 Aug; 125(Pt 8):1908-22. PubMed ID: 12135980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomes.
    Petr GT; Sun Y; Frederick NM; Zhou Y; Dhamne SC; Hameed MQ; Miranda C; Bedoya EA; Fischer KD; Armsen W; Wang J; Danbolt NC; Rotenberg A; Aoki CJ; Rosenberg PA
    J Neurosci; 2015 Apr; 35(13):5187-201. PubMed ID: 25834045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass Spectrometry Analysis of Wild-Type and Knock-in Q140/Q140 Huntington's Disease Mouse Brains Reveals Changes in Glycerophospholipids Including Alterations in Phosphatidic Acid and Lyso-Phosphatidic Acid.
    Vodicka P; Mo S; Tousley A; Green KM; Sapp E; Iuliano M; Sadri-Vakili G; Shaffer SA; Aronin N; DiFiglia M; Kegel-Gleason KB
    J Huntingtons Dis; 2015; 4(2):187-201. PubMed ID: 26397899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects.
    Faideau M; Kim J; Cormier K; Gilmore R; Welch M; Auregan G; Dufour N; Guillermier M; Brouillet E; Hantraye P; Déglon N; Ferrante RJ; Bonvento G
    Hum Mol Genet; 2010 Aug; 19(15):3053-67. PubMed ID: 20494921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The GLT-1 (EAAT2; slc1a2) glutamate transporter is essential for glutamate homeostasis in the neocortex of the mouse.
    Bjørnsen LP; Hadera MG; Zhou Y; Danbolt NC; Sonnewald U
    J Neurochem; 2014 Mar; 128(5):641-9. PubMed ID: 24224925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes.
    Chen LL; Wu JC; Wang LH; Wang J; Qin ZH; Difiglia M; Lin F
    Acta Pharmacol Sin; 2012 Mar; 33(3):385-92. PubMed ID: 22266730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Exogenous NUB1 Expression in the Striatum of HDQ175/Q7 Mice.
    Vodicka P; Chase K; Iuliano M; Valentine DT; Sapp E; Lu B; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M
    J Huntingtons Dis; 2016 Jun; 5(2):163-74. PubMed ID: 27314618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hippocampal Synaptic Dysfunction in a Mouse Model of Huntington Disease Is Not Alleviated by Ceftriaxone Treatment.
    Wilkie CM; Barnes JR; Benson CM; Brymer KJ; Nafar F; Parsons MP
    eNeuro; 2020; 7(3):. PubMed ID: 32354757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry.
    Runne H; Régulier E; Kuhn A; Zala D; Gokce O; Perrin V; Sick B; Aebischer P; Déglon N; Luthi-Carter R
    J Neurosci; 2008 Sep; 28(39):9723-31. PubMed ID: 18815258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.